Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BRAF in melanoma: biological and clinical challenges.

Critical reviews in oncology/hematology - 1 Sept 2013

Mandalà Mario, Voit Christiane

Abstract excerpt

Melanoma is an aggressive form of skin cancer that causes the greatest number of skin cancer-related deaths worldwide. In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies. A majority of cutaneous melanomas show activating mutations in the NRAS or BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 23415641
DOI: 10.1016/j.critrevonc.2013.01.003

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BRAF in melanoma: biological and clinical challenges.PMID 23415641Read ↗

BRAF in melanoma: current strategies and future directions.Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceSemantic proximity Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read ↗

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidenceSemantic proximity Read ↗

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Semantic proximity Read ↗

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Semantic proximity Read ↗

Narrative review: BRAF opens the door for therapeutic advances in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.